

This is a repository copy of *Bacterial competition and quorum-sensing signalling shapes the eco-evolutionary outcomes of model in vitro phage therapy*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/105397/>

Version: Accepted Version

Article:

Mumford, Rachel and Friman, Ville-Petri orcid.org/0000-0002-1592-157X (2016) Bacterial competition and quorum-sensing signalling shapes the eco-evolutionary outcomes of model in vitro phage therapy. *Evolutionary applications*. ISSN 1752-4571

<https://doi.org/10.1111/eva.12435>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

1 **Bacterial competition and quorum-sensing signalling shapes**
2 **the eco-evolutionary outcomes of model *in vitro* phage therapy**

3

4 **Authors:** Rachel Mumford¹ and Ville-Petri Friman^{1,2,*}

5

6 **Affiliations:**

7 ¹Imperial College London, Silwood Park Campus, Buckhurst Road, Ascot, Berkshire, SL5 7PY, UK

8 ²University of York, Department of Biology, Wentworth Way, York, YO10 5DD, UK

9 *Corresponding author

10

11 **E-mail:** Rachel Mumford (rachel-mumford@hotmail.co.uk); Ville-Petri Friman
12 (ville.friman@york.ac.uk)

13

14 **Article Type:** Original Research articles

15

16 **Running head:** Phage therapy in polymicrobial communities

17

18

19

20

21

22

23

24 **ABSTRACT**

25 The rapid rise of antibiotic resistance has renewed interest in phage therapy – the use of bacteria-
26 specific viruses (phages) to treat bacterial infections. Even though phages are often pathogen-
27 specific, little is known about the efficiency and eco-evolutionary outcomes of phage therapy in
28 polymicrobial infections. We studied this experimentally by exposing both quorum sensing (QS)
29 signalling PAO1 and QS-deficient *lasR Pseudomonas aeruginosa* genotypes (differing in their
30 ability to signal intra-specifically) to lytic PT7 phage in the presence and absence of two bacterial
31 competitors: *Staphylococcus aureus* and *Stenotrophomonas maltophilia* – two bacteria commonly
32 associated with *P. aeruginosa* in polymicrobial cystic fibrosis lung infections. Both the *P.*
33 *aeruginosa* genotype and the presence of competitors had profound effects on bacteria and phage
34 densities and bacterial resistance evolution. In general, competition reduced the *P. aeruginosa*
35 frequencies leading to a lower rate of resistance evolution. This effect was clearer with QS-
36 signalling PAO1 strain due to lower bacteria and phage densities and relatively larger pleiotropic
37 growth cost imposed by both phage and competitors. Unexpectedly, phage selection decreased the
38 total bacterial densities in the QS-deficient *lasR* pathogen communities, while an increase was
39 observed in the QS-signalling PAO1 pathogen communities. Together these results suggest that
40 bacterial competition can shape the eco-evolutionary outcomes of phage therapy.

41

42 **Keywords:** Competition, coevolution, cost of resistance, host-parasite interactions, phage therapy,
43 polymicrobial infections, quorum sensing signalling, resistance

44

45

46

47

48 **1. INTRODUCTION**

49 Growing concern for the evolution of antibiotic resistant bacteria and in particular for multi-
50 resistant gram-negative bacteria (Levy and Marshall 2004), has led to renewed interest in alternative
51 treatments including phage therapy (Rossolini et al. 2014). Phage therapy - the use of pathogen-
52 specific parasitic viruses (bacteriophages) as a treatment for bacterial infections - is almost hundred
53 years old and has been used for decades to treat bacterial infections in Eastern European countries
54 such as Georgia and Poland (Alisky et al. 1998; Housby and Mann 2009; Abedon et al. 2011).
55 While many studies have demonstrated the safety and benefits of phage therapy (Merabishvili et al.
56 2009; Abedon et al. 2011; Rose et al. 2014) phages have not yet been incorporated into western
57 medicine partly due to lack of proper clinical trials and historically inconsistent treatment results
58 (Kutateladze and Adamia 2008). While large-scale clinical trials are currently under way (e.g.
59 Phagoburn; (Expert round table on and re-implementation of bacteriophage 2016)), the evolutionary
60 outcomes of phage therapy are relatively unknown. Recent studies have shown that bacteria and
61 phages can rapidly coevolve during model phage-therapy treatments (Betts et al. 2013; Friman et al.
62 2016) and that the diversity of phage communities can affect the bacterial resistance evolution (Hall
63 et al. 2012; Betts et al. 2016). Besides rapid coevolution, further complications could arise from
64 interspecific bacterial competition due to polymicrobial nature of bacterial infections: many human
65 infections contain multiple different pathogenic bacterial and other microbial species (Peters et al.
66 2012). Considerable genotypic variation also exists between different strains of a pathogen and this
67 variation is known to differ between different patients and to affect the pathogen susceptibility to
68 phages (Debarbieux et al. 2010; Essoh et al. 2013; Friman et al. 2013). Understanding the relative
69 importance and interactive effects of these potentially complicating factors is thus crucial for
70 developing reliable and consistent phage therapy treatments. Here we focused explicitly on the
71 ecological and evolutionary outcomes of phage therapy in polymicrobial communities and asked
72 how focal bacterial genotype and the competition with other bacterial pathogens affect the total
73 bacterial loads and focal pathogen resistance evolution during *in vitro* model phage therapy.

74 The bacterium *Pseudomonas aeruginosa* is an opportunistic pathogen that commonly infects many
75 immunocompromised patients including cystic fibrosis (CF) and burn victim patients (Harrison
76 2007; Turner et al. 2014). *P. aeruginosa* is often characterised by multi-drug resistance to
77 conventional antibiotics (Strateva and Yordanov 2009), and hence, the development of novel phage
78 therapy treatments could potentially help a large number of patients (Harper and Enright 2011).
79 While *P. aeruginosa* can rapidly evolve resistance to various bacteriophages, which could decrease
80 the feasibility and long-term benefits of phage therapy (Hall et al. 2012; Betts et al. 2013; Friman et
81 al. 2013), it has also been shown that phages can counteract resistance evolution by coevolving to
82 be more infective (Betts et al. 2016; Friman et al. 2016). However, it is less clear how important
83 these coevolutionary dynamics are in more complex microbial communities. For example, lung and
84 wound infections are often very diverse and consist of multiple different non-pathogenic and
85 pathogenic bacterial species (Harrison 2007; Folkesson et al. 2012; Korgaonkar et al. 2013) that
86 could modify phage effects indirectly via competition.

87 Competition could affect the evolution of phage resistance via demographic and genetic
88 effects. Firstly, competition is likely to reduce focal pathogen population densities which could
89 weaken the selection for resistance due to less frequent phage-bacteria encounter rates and lowered
90 supply of resistance mutations (Levin and Bull 2004; Lopez-Pascua and Buckling 2008). These
91 demographic effects could be occurring indirectly via competition for shared resources in the site of
92 infection or directly via interference competition via bacteria-specific toxins such as bacteriocins
93 (Inglis et al. 2009; Ghoul et al. 2015). Furthermore, *P. aeruginosa* has been shown to display greater
94 virulence, antibiotic tolerance and growth when co-cultured with gram-positive *S. aureus* bacterium
95 (Korgaonkar et al. 2013; Michelsen et al. 2014), which suggests that the presence of other bacterial
96 species could also facilitate target pathogen coexistence in polymicrobial infections. Secondly, there
97 might be trade-offs between evolving phage resistance and retaining competitive ability or virulence
98 due to conflicting selection pressures (Friman and Buckling 2014). Such trade-offs are often
99 manifested as antagonistic pleiotropy where a mutation in the gene that confers benefit in the

100 presence of phage has a negative effect on some other function such as uptake of nutrients (Lenski
101 and Levin 1985). The magnitude of such trade-offs is often dependent on environmental conditions,
102 being larger in nutrient-poor environments (Yoshida, Hairston, and Ellner 2004) or in the presence
103 of competitors (Kassen 2002). Lastly, it has been shown that the presence of a phage can change the
104 competitive interactions between different bacterial species and that this effect depends on which
105 competing bacterial species is affected by the phage (Harcombe and Bull 2005).

106 The effect of competitors on focal pathogen fitness, and pathogen potential to evolve
107 resistance to phages, could further depend on the focal pathogen genotype. For example, *P.*
108 *aeruginosa* CF lung infections are genetically diverse and this heterogeneity is driven by both
109 temporal (Marvig et al. 2014) and spatial variation (Jorth et al. 2015). It has been recently shown
110 that phages can have a different effect on *P. aeruginosa* density and resistance evolution depending
111 on the strain and the genotype; specifically, the time bacteria spent adapting to the lung environment
112 seem to make bacteria more susceptible to phages (Friman et al. 2013; Friman et al. 2016). One
113 notable adaptation to the CF lung environment is the loss of quorum sensing related traits (Marvig
114 et al. 2014; Michelsen et al. 2014; Andersen et al. 2015). Quorum sensing (QS) is a means by which
115 bacteria communicate through the release of signalling molecules allowing cells to carry out
116 density-dependent gene expression (Miller and Bassler 2001). In *P. aeruginosa*, the ability to
117 quorum sense is critical for controlling behaviours such as the production of virulence factors
118 (Folkesson et al. 2012) and it is known that strains from acute infections (early colonisations) are
119 more virulent compared to strains from chronic infections (long-term colonisations) (Smith et al.
120 2006; Marvig et al. 2014). Interestingly, recent evidence suggests that QS-regulated genes can also
121 affect bacterial resistance to phages. For example, with *E. coli*, QS genes regulate resistance to
122 phage plastically via reduction of cell surface receptors (Hoyland-Kroghsbo, Maerkedahl, and
123 Svenningsen 2013; Taj et al. 2014). Similarly, QS has been shown to be an important ‘switch’ for
124 choosing between different anti-phage defence strategies in the bacterium *Vibrio anguillarum* (Tan,

125 Svenningsen, and Middelboe 2015). As a result, the decrease of phage resistance in *P. aeruginosa*
126 QS-mutants could be due to the loss of functional QS-genes.

127 Here we used *in vitro* experimental evolution approach to study the eco-evolutionary
128 outcomes of phage therapy with *P. aeruginosa* focal pathogen, that frequently co-infects the lungs
129 of CF patients (Harrison 2007). We manipulated both the presence of *Staphylococcus aureus* and
130 *Stenotrophomonas maltophilia* competitors (one or two competitors present - our definition of a
131 polymicrobial community from here on) and the PT7 phage, and used two *P. aeruginosa* pathogen
132 genotypes: QS-signalling PAO1 strain and QS-deficient *lasR* mutant strain, which does not produce
133 or respond to QS-signals (Diggle et al. 2007). These bacterial species were chosen because they
134 commonly coexist and infect humans patients suffering from burn wounds or cystic fibrosis (CF)
135 lung infections (Harrison 2007). We used fully factorial design where both *P. aeruginosa* genotypes
136 were evolved in all possible combinations and measured bacterial and phage densities and
137 coevolutionary changes between *P. aeruginosa* and PT7 phage at the end of the selection
138 experiment. We hypothesised that the rate of phage resistance evolution could be negatively
139 affected by competition via negative effects on population densities (lowered mutation supply rate
140 and phage-bacteria encounter rates) and that the effect of competition could further depend on the
141 focal pathogen genotype, the composition of competitor community, and the pleiotropic costs of
142 adaptation.

143

144 **2. MATERIALS AND METHODS**

145 *Bacterial and phage strains*

146 In addition to *Pseudomonas aeruginosa* (Diggle et al. 2007), we used *Staphylococcus aureus subsp.*
147 *aureus* (DSM-20231) and *Stenotrophomonas maltophilia* (DSM-50170) bacteria in our
148 experiments. We chose *P. aeruginosa* as our focal species as it is one of the most common causes of
149 morbidity for CF patients, while *S. aureus* and *S. maltophilia* often coexist with *P. aeruginosa*
150 among *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Burkholderia cenocepacia*, *Ralstonia*

151 *and Achromobacter* (Jelsbak et al. 2007; Folkesson et al. 2012). To compare the effect of pathogen
152 genotype, two strains of *Pseudomonas aeruginosa* were used: QS-signalling PAO1 and QS-
153 deficient PAO1 *lasR* mutant strains (Diggle et al. 2007). Apart from the mutation in QS-signalling
154 pathway, the two isolates were otherwise isogenic (Fletcher et al. 2007). The *lasR* mutation is often
155 associated with isolates from the later stages of long-term infections in CF patients (Marvig et al.
156 2014; Andersen et al. 2015) and its weakened virulence is due to inability to detect and produce
157 quorum sensing signalling molecules that activate the expression of *P. aeruginosa* virulence factors
158 (Smith et al. 2006). A lytic bacteriophage, PT7, which obligately kills *P. aeruginosa*, was used as a
159 phage (Friman et al. 2016). Relatively little is known about PT7 phage. Even though its genome has
160 not been sequenced, previous studies suggest that it is not closely related to PB1-like or phiKMV-
161 like phages (Merabishvili et al. 2007). Similarly, it is unclear which receptors it uses to infect *P.*
162 *aeruginosa*. Prior the experiment, we confirmed that phage PT7 was not able to infect *S. aureus* or *S.*
163 *maltophilia* (tested with streak assays), and that the presence of *S. aureus* or *S. maltophilia* had no
164 effect on phage densities during short-term co-cultivation (24h). Moreover, both the PAO1 and *lasR*
165 strains were susceptible to phage PT7 in the beginning of the experiment (streak assays) yielding
166 similar phage population densities (phage efficiency of plating with plaque assay: $\sim 10^8$ phage
167 particles mL⁻¹ from the same ancestral phage stock).

168

169 ***Experimental design, growth conditions and selection experiment***

170 We used a factorial design to independently manipulate bacterial community composition, the
171 presence of phage and *P. aeruginosa* genotype. To this end, *P. aeruginosa* focal pathogen strains,
172 PAO1 and *lasR*, were evolved in both the absence and presence of phage under four different
173 competition treatments: alone, with *S. aureus*, with *S. maltophilia* and with both *S. aureus* and *S.*
174 *maltophilia*. Each treatment (16 in total) was replicated five times.

175 The communities were grown in 1.5 mL of 10% nutrient broth (NB) media (containing 0.5g
176 peptone and 0.3g beef extract per litre distilled water) in deep 96-well plates (Starlab; 2.2 mL of

177 total volume). All treatments were inoculated with approximately 3.8×10^5 bacterial cells per mL,
178 where two-competitor treatments were inoculated with 1:1 ratio of both bacteria and three-
179 competitor treatments with 1:1:1 ratio of every bacteria. Approximately 1.5×10^8 phage particles
180 were added to all phage treatments. All populations were incubated as static cultures at 37°C to
181 reflect human body temperature. The selection experiment was run for 16 days with transfers
182 carried out every fourth day. At each transfer, the cultures were first mixed and homogenised using
183 a pipette before an inoculum of 250 µL was transferred to new deep-well plates containing 1.5 mL
184 fresh media in each well, after 500 µL of each microbial community was cryopreserved in 20% of
185 glycerol at -80°C. Given nutrient broth concentration was chosen to allow prolonged growth during
186 4-day transfer intervals and to reduce the *P. aeruginosa* biofilm and exopolymer production.

187

188 ***Bacterial and phage density measurements***

189 Bacterial densities were measured only at the end of the experiment by serially diluting the samples
190 isolated from the last time point and plating out 10µl of each dilution onto NB agar plates (100%
191 NB media supplemented with 12g agar per litre). To determine *P. aeruginosa* densities in multi-
192 species communities, community treatment samples were also plated on *Pseudomonas* selective
193 agar plates (16g Peptic digest of animal tissue, 10g Casein enzymic hydrolysate, 10g K₂SO₄, 1.4g
194 MgCl₂ • 6H₂O, 10ml glycerol and 11g Agar per litre with 200mg C-N selective supplement
195 dissolved in 4ml 1:1 ethanol:distilled water). Bacteria were incubated at 37°C for 48 hours before
196 counting the colonies and calculating the number of colony forming units (CFU) per ml. At every
197 transfer, phages were extracted by mixing with 10% chloroform to kill the bacteria. After vortexing
198 and centrifugation, chloroform-free phage supernatants were stored at 4°C. Phage densities were
199 estimated at every transfer with plaque assays where phage densities are defined as growth on a
200 lawn of ancestral PAO1 bacterial strain. PAO1 ancestral strain was grown at 37°C for 24hours and
201 200µl of this culture was then mixed with 20ml of 50°C soft agar and poured in an even overlay
202 over square NB agar plates. A 10µl of phage serial dilutions ($10^{-4} - 10^{-7}$) was then pipetted onto the

203 surface of the pseudomonas-agar overlay, plates were incubated at 37°C for 24 hours, and the
204 number of phage plaques, i.e. phage particles, counted.

205

206 ***Phage resistance assays***

207 A streak assay methodology was used to estimate the evolution of bacterial resistance and phage
208 infectivity (Buckling and Rainey 2002). 12 randomly chosen colonies per each *P. aeruginosa*
209 population were isolated at the end of the experiment and grown in 96-well microplates at 37°C in
210 150µl of NB media. After 24-hour growth, colonies were cryopreserved at -80°C as above for
211 evolutionary analyses. Phage resistance was measured by pipetting 25µl of phage in a line across
212 square NB plates. A sterilised 12-pin replicator (V&P Scientific) was then used to streak 12
213 bacterial colonies across the dried line of phage. Plates were incubated at 37°C for 24 hours (or
214 until the bacterial streak became visible). Colonies with a clear reduction in growth over the phage
215 line were scored as susceptible (0) and with normal growth over the phage as resistant (1). Phage
216 resistance was determined at the population level in terms of a proportion of resistant colonies per
217 population. All *P. aeruginosa* colonies were tested against the ancestral PT7 phage and evolved PT7
218 phages isolated from their own population (coevolved phage population isolated by the way of
219 chloroforming as described above).

220

221 ***Measuring the pleiotropic cost of adaptation***

222 The pleiotropic cost of adaptation was measured as the final bacterial density at 48h by using the
223 same colonies that were used in the phage resistance assays. Colonies were inoculated in 96-well
224 microplates containing 200µl NB media per well by using a sterilised 96-pin replicator (Boenik).
225 The plates were then grown at 37°C and optical density (OD₆₀₀) measurements taken after 48 hours.
226 The growth of the colonies, which had been subjected to competition and or phages in the selection
227 experiment was compared to colonies that had evolved alone. A mean population density was
228 calculated for all the colonies isolated from the same population. Even though this method results in

229 indirect fitness measures it was the only practical way to estimate the cost due to a high number of
230 evolved clones (960 clones).

231

232 *Statistical analysis*

233 All models and test statistics are presented in the supplementary tables 1-5. For the bacterial density
234 data, a linear model was fitted predicting square root transformed *P. aeruginosa* density as a
235 function of phage treatment, competition and pathogen genotype. For the phage density data, a
236 mixed model was used for log transformed phage density data as a function of competition and
237 pathogen genotype with time set as a repeated factor. For the phage resistance data, a linear model
238 was fitted predicting arcsin transformed resistance data as a function of phage evolution (ancestral or
239 coevolved), pathogen genotype, and competition. A similar model was used for data predicting the
240 cost of adaptation with the exception that untransformed bacterial growth data was used for the
241 analysis. Post hoc tukey honest significance difference tests were carried out to further investigate
242 significant interactions between factor levels. All analyses were conducted in R, version 3.1.2.
243 (Team. 2014).

244 **3. RESULTS**

245 *Bacterial and phage densities during the selection experiment*

246 Both phages ($F_{1,64} = 8.67$, $p=0.005$) and competitors ($F_{3,64} = 48.80$, $p<0.001$) significantly reduced
247 *P. aeruginosa* densities in the end of the selection experiment (Fig. 1a-b, Supplementary Table 1). In
248 the absence of phages, both PAO1 and *lasR* monocultures had higher *P. aeruginosa* densities
249 compared to all polymicrobial communities, and PAO1 strain reached higher population densities
250 compared to *lasR* strain when evolving in the absence of a phage and competitors ($p<0.001$ for all
251 comparisons). However, the relative effect of competition was stronger for the PAO1 strain
252 (genotype \times competition: $F_{3,64} = 5.02$, $p=0.003$). Moreover, phages reduced the densities of PAO1
253 strain more compared to a *lasR* strain (phage \times competition: $F_{3,64} = 7.70$, $p<0.001$). The phage
254 effect depended also on the type of competitive community: in general, phage had a negative effect

255 on *P. aeruginosa* in the presence of *S. aureus* regardless of the pathogen genotype, while phages had
256 mainly non-significant effects in the other polymicrobial communities (and even a positive effect in
257 the presence of *S. maltophilia*, Fig. 1a-b). Unexpectedly, phage selection also affected the total
258 bacterial biomasses in the polymicrobial communities (Fig. 1c, supplementary table 2) by
259 increasing the total bacterial densities in the PAO1 communities, and decreasing the total bacterial
260 densities in the *lasR* communities in general (genotype \times phage: $F_{1,56} = 8.04$, $p=0.006$; the effect
261 varied depending on the community composition, supplementary figure 1).

262 Phage densities decreased during the selection experiment in general (Time: $F_{3,30.35} = 17.34$,
263 $p<0.001$, Fig. 2a-b, Supplementary table 3). While competition had no significant main effect on the
264 phage densities, a significant interaction was found: even though competition had no effect in the
265 weakly virulent pathogen communities, it reduced the phage densities in the PAO1 pathogen
266 communities (genotype \times competition: $F_{1,32.1} = 2.96$, $p=0.047$, Fig. 2a-b). The number or type of
267 competitors did not affect the phage densities with either PAO1 or *lasR* strain ($p>0.05$ in all
268 comparisons). Together these results suggest that competitors had stronger negative effects on both
269 the bacteria and phages in the PAO1 compared to *lasR* pathogen communities.

270

271 ***Bacteria-phage coevolution in different communities***

272 Both initially susceptible PAO1 and *lasR* strains evolved increased levels of resistance to ancestral
273 phage (Fig. 3a-b, supplementary table 4), while the *lasR* strain evolved higher levels of resistance
274 compared to the PAO1 strain in general (genotype: $F_{1,62} = 35.94$, $p<0.001$). While competitors had
275 no effect on the *lasR* strain resistance evolution, they generally constrained PAO1 resistance
276 evolution (phage origin \times competition: $F_{1,62} = 6.94$, $p<0.001$) with all competitive communities
277 having similar effects ($p>0.05$ in all comparisons). We also found that phages coevolved to become
278 more infective during the selection experiment (Fig. 3a-b): the resistance of evolved bacteria was
279 lower when measured against evolved compared to ancestral phages (phage origin: $F_{1,62} = 25.38$
280 $p<0.001$). Interestingly, PAO1 resistance was less affected by phage coevolutionary history

281 (ancestral vs. coevolved) compared to *lasR* strain (phage origin \times genotype: $F_{1, 62} = 4.15$, $p=0.046$).
282 Together these results suggest that competition altered the trajectory of bacteria–phage co-
283 evolution.

284

285 *Pleiotropic cost of adaptation*

286 Coevolutionary history with the phage led to reduced bacterial growth in the absence of phages ($F_{1, 71}$,
287 $\gamma_1 = 13.36$, $p<0.001$, Fig. 4a-b, Supplementary table 5). While the focal pathogen genotype ($F_{1, 71} =$
288 2.34 , $p=0.131$) or the presence of competitors ($F_{1, 71} = 1.88$, $p=0.175$) had non-significant main
289 effects on the pathogen growth, the growth cost imposed by phage selection was larger with the
290 PAO1 strain (genotype \times phage: $F_{1, 71}=6.27$, $p=0.015$). Moreover, already the presence of
291 competitors led to reduced PAO1 strain growth in the absence of phage selection (genotype
292 \times competition: $F_{1, 71} = 7.08$, $p=0.010$; all competitive communities had similar effects: $F_{3, 63} = 2.38$,
293 $p=0.078$). Consistent with the population density data, the evolved PAO1 strain reached higher
294 population densities compared to *lasR* strain when bacteria had evolved in the absence of a phage
295 and competitors (genotype \times phage: $F_{1, 71}=6.27$, $p=0.015$). These results suggest that even though
296 both pathogen genotypes suffered from a reduced growth due to phage selection in monocultures,
297 only the PAO1 strain was affected by the presence of competitors and hence suffered relatively
298 higher pleiotropic cost of adaptation in polymicrobial communities.

299

300 **4. DISCUSSION**

301 Here we studied the role of bacterial competition for the efficiency and eco-evolutionary outcomes
302 of phage therapy in model polymicrobial infections *in vitro*. We found that both phages and
303 competitors reduced the focal pathogen densities. However, this effect was strongly dependent on
304 the focal pathogen genotype with both competitors and phage having a more severe effect on the
305 QS-signalling PAO1 strain. The negative effects of competition observed at the population level
306 correlated with reduced rate of resistance evolution. Interestingly, phage presence decreased the

307 total bacterial densities in *lasR* pathogen communities demonstrating an unexplored potential
308 benefit of phage therapy: indirect, community-wide reduction in pathogenic bacterial loads in
309 polymicrobial infections. However, a converse pattern was observed in PAO1 communities, which
310 suggest that phages could also indirectly worsen the polymicrobial infections by increasing the
311 density of other pathogenic bacteria. Together these results suggest that phage-mediated effects
312 depend on bacterial competition and the focal pathogen genotype pinpointing the need to
313 understand eco-evolutionary consequences of phage therapy in the community context.

314 Both competitors and phage had a negative effect on *P. aeruginosa* densities while the effect
315 of competition was relatively larger compared to the effect of a phage. While the number or the
316 composition of competitive communities had no clear effects on *P. aeruginosa* densities, the effect
317 of competition depended on the *P. aeruginosa* genotype being more severe for the PAO1 compared
318 to *lasR* strain in general. This suggests that QS may play an important role for *P. aeruginosa*
319 competition against other bacterial species. For example, the proportion of *lasR* mutants typically
320 increases during chronic polymicrobial CF-infections (Smith et al. 2006; Marvig et al. 2014; Ghoul
321 et al. 2015) and this could be potentially partly explained with QS-mediated competitive
322 interactions with other bacteria (Harrison et al. 2008). There are several mutually nonexclusive
323 explanations for reduced *P. aeruginosa* growth in the presence of competitors. First, competition for
324 limited resources was likely stronger in the presence of other bacterial species leading to lower *P.*
325 *aeruginosa* densities in polymicrobial pathogen communities. Second, interference competition
326 could have directly reduced *P. aeruginosa* growth directly. For example, *S. maltophilia* has been
327 observed to influence *P. aeruginosa* biofilm architecture and protein synthesis (Ryan et al. 2008),
328 while *P. aeruginosa* has been shown to have negative effects on *S. aureus* due to upregulation of
329 antistaphylococcal substances such as pyocyanin and phenazine (Michelsen et al. 2014). Even
330 though *S. aureus* has not been shown to have direct negative effects on *P. aeruginosa*, the *S. aureus*
331 presence has been shown to favour the increase in the frequency of QS-deficient mutants (Harrison
332 et al. 2008). In line with this study, it has been found that a QS-positive PAO1 strain interacts more

333 negatively with *S. aureus* compared to a QS-negative *lasR* strain (Michelsen et al. 2014). Recent
334 evidence suggests that reduced antagonism between *S. aureus* on *P. aeruginosa lasR* mutants could
335 be due to metabolic divergence (Frydenlund Michelsen et al. 2015). However, more detailed
336 community level experiments are needed to understand these dynamics more profoundly.

337 The negative effect of phage was clearest in PAO1 monoculture and generally in the
338 presence of *S. aureus* with both pathogen genotypes. The presence of *S. maltophilia* did not affect
339 phage efficiency with the PAO1 strain and even increased the *lasR* densities in the presence of
340 phage (Fig. 1a-b), while phage had no effects on *P. aeruginosa* densities in the presence of both *S.*
341 *maltophilia* and *S. aureus*. Together these results suggest that phages can reduce *P. aeruginosa*
342 densities additively in the presence of competitors but that this effect depends on the strength of
343 competition and the composition of the competing bacterial community. Interestingly, phage
344 presence decreased and increased the total bacterial densities of polymicrobial *lasR* and PAO1
345 communities, respectively. Reduction in PAO1 frequency by the phage could have led to a
346 competitive release and increased the growth of *S. aureus*, *S. maltophilia* and total bacterial
347 densities. Conversely, resource competition was likely more intense and more symmetric within
348 *lasR* communities due to stronger levels of phage resistance evolution (and hence higher *P.*
349 *aeruginosa* density). Lastly, it has been shown that phage selection can impose relatively higher
350 competitive cost for the PAO1 compared to the *lasR* strain due to upregulation of siderophore
351 production (Vasse, Torres-Barcelo, and Hochberg 2015). Such metabolic cost could also potentially
352 explain relatively poorer PAO1 growth in the presence of competitors even in the non-social culture
353 conditions used in this experiment. In addition to demographic explanations, the potential changes
354 at the gene expression level warrant thus further investigation in the future.

355 In line with the bacterial density data, the phage abundances were also generally
356 lower in the presence of competitors and this effect was clearer with the PAO1 strain that suffered
357 more heavily from competition compared to the *lasR* strain. Competition-mediated reduction in
358 bacterial and phage densities correlated with reduced levels of resistance evolution, and as a result,

359 PAO1 strain evolved lower levels of resistance compared to the *lasR* strain. Simple demographic
360 effects that weaken the strength of selection via reduced bacteria and phage encounter rates and
361 lowered mutation supply rate (Lopez-Pascua and Buckling 2008) could thus be important for the
362 evolutionary outcomes of phage therapy in polymicrobial infections. We also found that phages
363 coevolved to be more infective during the selection experiment as demonstrated by higher levels of
364 resistance of evolved bacteria to the ancestral compared to evolved phage populations. In line with
365 the population dynamics data, the coevolutionary signal was stronger in *lasR* pathogen communities
366 where both bacterial and phage densities were also higher. Bacterial competition did not thus
367 constrain only the bacterial resistance but also the phage infectivity evolution and the trajectory of
368 phage-bacteria coevolution.

369 Also, some underlying genetic differences could have affected PAO1 and *lasR* strain
370 response to phages. It has been shown that removing, altering and concealing cell surface receptors
371 can prevent phage adsorption (Seed 2015) and that a functional QS system is important for
372 regulating such phage defences (Hoyland-Kroghsbo, Maerkedahl, and Svenningsen 2013; Taj et al.
373 2014; Tan, Svenningsen, and Middelboe 2015). In contrast to these findings, we found that QS-
374 defective strains were able to evolve higher levels of resistance to phages especially in the presence
375 of bacterial competitors. A similar pattern has been found before, where the loss of QS impaired
376 bacterial twitching motility leading to elevated resistance to pili-specific phages (Glessner et al.
377 1999). Even though the PT7 target receptor is unknown, both the PAO1 and *lasR* strains were
378 equally susceptible to the phage in the beginning of the experiment. This suggests that initial
379 differences in PAO1 and *lasR* strains' QS ability unlikely drove the long-term differences in the
380 bacterial resistance and phage infectivity evolution. Phage receptors are also often important for
381 other purposes including nutrient uptake (Lenski and Levin 1985), and hence, mutations in phage
382 receptors often reduce bacterial competitive ability. In support for this, we found that both evolved
383 PAO1 and *lasR* monoculture strains suffered reduced growth in the absence of phages and
384 competitors if they had evolved in the presence of a phage during the selection experiment.

385 Interestingly, while competitors increased the magnitude of the growth cost with PAO1 strain,
386 competitors had no effect or even a positive effect on *lasR* growth. One explanation for this is that
387 less antagonistic interactions between the *lasR* and competitors allowed more rapid accumulation of
388 compensatory mutations during the selection experiment due to relatively large population size and
389 mutation supply rate compared to PAO1 strain. We also found that evolved PAO1 strain grew better
390 in the growth media compared to *lasR* strain when the bacteria had evolved in the absence of a
391 phage and competitors. This suggest that functional QS-system could help *P. aeruginosa* to adapt to
392 abiotic environmental conditions potentially due to depressing of growth-limiting intracellular
393 metabolism (Asfahl et al. 2015). In the community context our results suggest that even though both
394 focal pathogen genotypes were able to evolve resistance to phage the PAO1 strain suffered more
395 severe costs of adaptation due to both competition and phage.

396 Our results have important implications for the development of phage therapies in the
397 context of polymicrobial infections. First, selection for phage resistance could be weaker in
398 polymicrobial communities due to a competition-mediated reduction in the focal pathogen density
399 and relatively higher pleiotropic costs of adaptation. Competition could thus enhance the phage
400 efficacy when treating acute CF and burn infections that are commonly co-infected by QS-
401 signalling *P. aeruginosa*, *S. aureus* and *S. maltophilia* (Harrison 2007; Turner et al. 2014). However,
402 in contrary, *P. aeruginosa* resistance evolution to phages could be a more severe problem in chronic
403 polymicrobial CF infections that are often dominated by *P. aeruginosa* mutants that have lost QS-
404 signalling ability during the long-term adaptation (Smith et al. 2006; Marvig et al. 2014; Andersen
405 et al. 2015). Interestingly, we found that higher levels of *lasR* strain resistance evolution were
406 correlated with the higher rate of phage infectivity evolution, which could open up avenues for pre-
407 adapting phages to be more infective before clinical phage therapy treatments (Betts et al. 2013;
408 Friman et al. 2016). Moreover, it would be interesting to investigate if our results hold when
409 multiple phage species are applied as a phage cocktail. We also want note that it is possible that
410 both *S. aureus* and *S. maltophilia* strains evolved during the selection experiment. For example, it is

411 known that *P. aeruginosa* can promote the formation of small colony variants with *S. aureus* leading
412 to changes in virulence and antibiotic resistance (Hoffman et al. 2006; Frydenlund Michelsen et al.
413 2015). It is thus important to expand the study the evolutionary effects of competition and phage
414 selection across the whole polymicrobial community in the future and also link these phenotypic
415 changes with the changes at the genotypic level.

416 In conclusion, here we show that the presence of competitors can modulate the phage-
417 mediated effects on a focal pathogen. Crucially, phage selection imposed weaker selection for
418 resistance evolution when the effect of competition with the focal pathogen was strong. Moreover,
419 while the phage presence indirectly reduced the total bacterial loads in weakly virulent *lasR*
420 pathogen communities, phages increased the total bacterial densities in highly virulent PAO1
421 pathogen communities. Bacterial competition is thus likely to be an important factor affecting both
422 the ecological and evolutionary outcomes of phage therapy in polymicrobial infections. From a
423 therapeutic perspective, the fact that overwhelming phage numbers were not able to eradicate
424 *Pseudomonas* even in the presence of competitors reinforces the importance of studying phage-
425 bacteria interactions in the polymicrobial context.

426

427 **Acknowledgements**

428 We thank Dr Stephen Diggle for providing the *P. aeruginosa* strains and Imperial College Junior
429 Research Fellowship program, Wellcome Trust and British Ecological Society for the funding
430 (VPF).

431

432 **Data Archiving Statement**

433 Data available from the Dryad Digital Repository: <http://dx.doi.org/xxxxx>

434

435 **References**

- 436 Abedon, S. T., S. J. Kuhl, B. G. Blasdel, and E. M. Kutter. 2011. Phage treatment of human
437 infections. *Bacteriophage* 1 (2):66-85.
- 438 Alisky, J., K. Iczkowski, A. Rapoport, and N. Troitsky. 1998. Bacteriophages show promise as
439 antimicrobial agents. *Journal of Infection* 36 (1):5-15.
- 440 Andersen, S. B., R. L. Marvig, S. Molin, H. Krogh Johansen, and A. S. Griffin. 2015. Long-term
441 social dynamics drive loss of function in pathogenic bacteria. *Proc Natl Acad Sci U S A* 112
442 (34):10756-61.
- 443 Asfahl, Kyle L, Jessica Walsh, Kerrigan Gilbert, and Martin Schuster. 2015. Asfahl et al 2015 Non-
444 social adaptation defers a tragedy of the commons in *Pseudomonas aeruginosa* quorum
445 sensing. *ISME J* 9:1734–1746.
- 446 Betts, A., D. R. Gifford, R. C. MacLean, and K. C. King. 2016. Parasite diversity drives rapid host
447 dynamics and evolution of resistance in a bacteria-phage system. *Evolution*.
- 448 Betts, Alex, Marie Vasse, Oliver Kaltz, and Michael E. Hochberg. 2013. Back to the future:
449 evolving bacteriophages to increase their effectiveness against the pathogen *Pseudomonas*
450 *aeruginosa* PAO1. *Evolutionary Applications* 6 (7):1054-1063.
- 451 Buckling, A. and P. B. Rainey. 2002. Antagonistic coevolution between a bacterium and a
452 bacteriophage. *Proc Biol Sci* 269 (1494):931-6.
- 453 Debarbieux, L., D. Leduc, D. Maura, E. Morello, A. Criscuolo, O. Grossi, V. Balloy, and L. Touqui.
454 2010. Bacteriophages can treat and prevent *Pseudomonas aeruginosa* lung infections. *The*
455 *Journal of infectious diseases* 201 (7):1096-104.
- 456 Diggle, S. P., A. S. Griffin, G. S. Campbell, and S. A. West. 2007. Cooperation and conflict in
457 quorum-sensing bacterial populations. *Nature* 450 (7168):411-4.
- 458 Essoh, C., Y. Blouin, G. Loukou, A. Cablanmian, S. Lathro, E. Kutter, H. V. Thien, G. Vergnaud,
459 and C. Pourcel. 2013. The Susceptibility of *Pseudomonas aeruginosa* Strains from Cystic
460 Fibrosis Patients to Bacteriophages. *PLoS One* 8 (4):e60575.

- 461 Expert round table on, acceptance and therapy re-implementation of bacteriophage. 2016. Silk route
462 to the acceptance and re-implementation of bacteriophage therapy. *Biotechnology Journal*
463 11 (5):595-600.
- 464 Fletcher, M. P., S. P. Diggle, S. A. Crusz, S. R. Chhabra, M. Camara, and P. Williams. 2007. A dual
465 biosensor for 2-alkyl-4-quinolone quorum-sensing signal molecules. *Environmental*
466 *microbiology* 9 (11):2683-93.
- 467 Folkesson, A., L. Jelsbak, L. Yang, H. K. Johansen, O. Ciofu, N. Hoiby, and S. Molin. 2012.
468 Adaptation of *Pseudomonas aeruginosa* to the cystic fibrosis airway: an evolutionary
469 perspective. *Nature Reviews Microbiology* 10 (12):841-851.
- 470 Friman, V. P., D. Soanes-Brown, P. Sierocinski, S. Molin, H. K. Johansen, M. Merabishvili, J. P.
471 Pirnay, D. De Vos, and A. Buckling. 2016. Pre-adapting parasitic phages to a pathogen leads
472 to increased pathogen clearance and lowered resistance evolution with *Pseudomonas*
473 *aeruginosa* cystic fibrosis bacterial isolates. *Journal of evolutionary biology* 29 (1):188-198.
- 474 Friman, Ville-Petri and Angus Buckling. 2014. Phages can constrain protist predation-driven
475 attenuation of *Pseudomonas aeruginosa* virulence in multienemy communities. *ISME J*
476 8:1820-1830.
- 477 Friman, Ville-Petri, Melanie Ghoul, Søren Molin, Helle Krogh Johansen, and Angus Buckling.
478 2013. *Pseudomonas aeruginosa* Adaptation to Lungs of Cystic Fibrosis Patients Leads to
479 Lowered Resistance to Phage and Protist Enemies. *PLoS One* 8 (9):e75380.
- 480 Frydenlund Michelsen, C., S. M. Hossein Khademi, H. Krogh Johansen, H. Ingmer, P. C.
481 Dorrestein, and L. Jelsbak. 2015. Evolution of metabolic divergence in *Pseudomonas*
482 *aeruginosa* during long-term infection facilitates a proto-cooperative interspecies interaction.
483 *ISME J*.
- 484 Ghoul, M., S. A. West, H. K. Johansen, S. Molin, O. B. Harrison, M. C. Maiden, L. Jelsbak, J. B.
485 Bruce, and A. S. Griffin. 2015. Bacteriocin-mediated competition in cystic fibrosis lung
486 infections. *Proc Biol Sci* 282 (1814).

- 487 Glessner, A., R. S. Smith, B. H. Iglewski, and J. B. Robinson. 1999. Roles of *Pseudomonas*
488 *aeruginosa* las and rhl quorum-sensing systems in control of twitching motility. *Journal of*
489 *Bacteriology* 181 (5):1623-1629.
- 490 Hall, A. R., D. De Vos, V. P. Friman, J. P. Pirnay, and A. Buckling. 2012. Effects of sequential and
491 simultaneous applications of bacteriophages on populations of *Pseudomonas aeruginosa* in
492 vitro and in wax moth larvae. *Applied and environmental microbiology* 78 (16):5646-52.
- 493 Harcombe, W. R. and J. J. Bull. 2005. Impact of phages on two-species bacterial communities.
494 *Applied and environmental microbiology* 71 (9):5254-9.
- 495 Harper, D. R. and M. C. Enright. 2011. Bacteriophages for the treatment of *Pseudomonas*
496 *aeruginosa* infections. *Journal of applied microbiology* 111 (1):1-7.
- 497 Harrison, F. 2007. Microbial ecology of the cystic fibrosis lung. *Microbiology-Sgm* 153:917-923.
- 498 Harrison, F., J. Paul, R. C. Massey, and A. Buckling. 2008. Interspecific competition and
499 siderophore-mediated cooperation in *Pseudomonas aeruginosa*. *ISME J* 2 (1):49-55.
- 500 Hoffman, L. R., E. Deziel, D. A. D'Argenio, F. Lepine, J. Emerson, S. McNamara, R. L. Gibson, B.
501 W. Ramsey, and S. I. Miller. 2006. Selection for *Staphylococcus aureus* small-colony
502 variants due to growth in the presence of *Pseudomonas aeruginosa*. *Proceedings of the*
503 *National Academy of Sciences of the United States of America* 103 (52):19890-19895.
- 504 Housby, J. N. and N. H. Mann. 2009. Phage therapy. *Drug Discov Today* 14 (11-12):536-40.
- 505 Hoyland-Krogsho, N. M., R. B. Maerkedahl, and S. L. Svenningsen. 2013. A quorum-sensing-
506 induced bacteriophage defense mechanism. *MBio* 4 (1):e00362-12.
- 507 Inglis, R. F., A. Gardner, P. Cornelis, and A. Buckling. 2009. Spite and virulence in the bacterium
508 *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 106 (14):5703-7.
- 509 Jelsbak, L., H. K. Johansen, A. L. Frost, R. Thogersen, L. E. Thomsen, O. Ciofu, L. Yang, J. A.
510 Haagensen, N. Hoiby, and S. Molin. 2007. Molecular epidemiology and dynamics of
511 *Pseudomonas aeruginosa* populations in lungs of cystic fibrosis patients. *Infection and*
512 *immunity* 75 (5):2214-24.

- 513 Jorth, P., B. J. Staudinger, X. Wu, K. B. Hisert, H. Hayden, J. Garudathri, C. L. Harding, M. C.
514 Radey, A. Rezayat, G. Bautista, W. R. Berrington, A. F. Goddard, C. Zheng, A. Angermeyer,
515 M. J. Brittnacher, J. Kitzman, J. Shendure, C. L. Fligner, J. Mittler, M. L. Aitken, C. Manoil,
516 J. E. Bruce, T. L. Yahr, and P. K. Singh. 2015. Regional Isolation Drives Bacterial
517 Diversification within Cystic Fibrosis Lungs. *Cell Host Microbe* 18 (3):307-319.
- 518 Kassen, R. 2002. The experimental evolution of specialists, generalists, and the maintenance of
519 diversity. *Journal of evolutionary biology* 15 (2):173-190.
- 520 Korgaonkar, A., U. Trivedi, K. P. Rumbaugh, and M. Whiteley. 2013. Community surveillance
521 enhances *Pseudomonas aeruginosa* virulence during polymicrobial infection. *Proc Natl Acad*
522 *Sci U S A* 110 (3):1059-64.
- 523 Kutateladze, M. and R. Adamia. 2008. Phage therapy experience at the Eliava Institute. *Medecine*
524 *Et Maladies Infectieuses* 38 (8):426-430.
- 525 Lenski, R. E. and B. R. Levin. 1985. Constraints on the Coevolution of Bacteria and Virulent Phage
526 - a Model, Some Experiments, and Predictions for Natural Communities. *American*
527 *Naturalist* 125 (4):585-602.
- 528 Levin, B. R. and J. J. Bull. 2004. Population and evolutionary dynamics of phage therapy. *Nature*
529 *Reviews Microbiology* 2 (2):166-173.
- 530 Levy, S. B. and B. Marshall. 2004. Antibacterial resistance worldwide: causes, challenges and
531 responses. *Nature medicine* 10 (12 Suppl):S122-9.
- 532 Lopez-Pascua, L. C. and A. Buckling. 2008. Increasing productivity accelerates host-parasite
533 coevolution. *J Evol Biol* 21 (3):853-60.
- 534 Marvig, R.L. , L.M. Madsen, S. Molin, and H.K. Johansen. 2014. Convergent evolution and
535 adaptation of *Pseudomonas aeruginosa* within patients with cystic fibrosis. *Nature genetics*
536 47:57-64.
- 537 Merabishvili, M., J. P. Pirnay, G. Verbeken, N. Chanishvili, M. Tediashvili, N. Lashkhi, T. Glonti, V.
538 Krylov, J. Mast, L. Van Parys, R. Lavigne, G. Volckaert, W. Mattheus, G. Verween, P. De

- 539 Corte, T. Rose, S. Jennes, M. Zizi, D. De Vos, and M. Vaneechoutte. 2009. Quality-
540 controlled small-scale production of a well-defined bacteriophage cocktail for use in human
541 clinical trials. *PLoS One* 4 (3):e4944.
- 542 Merabishvili, Maia, Rita Verhelst, Thea Glonti, Nino Chanishvili, Victor Krylov, Claude Cuvelier,
543 Marina Tediashvili, and Mario Vaneechoutte. 2007. Digitized fluorescent RFLP analysis
544 (frRFLP) as a universal method for comparing genomes of culturable dsDNA viruses:
545 application to bacteriophages. *Research in Microbiology* 158 (7):572-581.
- 546 Michelsen, C. F., A. M. Christensen, M. S. Bojer, N. Hoiby, H. Ingmer, and L. Jelsbak. 2014.
547 Staphylococcus aureus alters growth activity, autolysis, and antibiotic tolerance in a human
548 host-adapted *Pseudomonas aeruginosa* lineage. *J Bacteriol* 196 (22):3903-11.
- 549 Miller, M. B. and B. L. Bassler. 2001. Quorum sensing in bacteria. *Annual Review of Microbiology*
550 55:165-99.
- 551 Peters, B. M., M. A. Jabra-Rizk, G. A. O'May, J. W. Costerton, and M. E. Shirtliff. 2012.
552 Polymicrobial Interactions: Impact on Pathogenesis and Human Disease. *Clinical*
553 *Microbiology Reviews* 25 (1):193-+.
- 554 Rose, Thomas, Gilbert Verbeken, Daniel De Vos, Maya Merabishvili, Mario Vaneechoutte, Rob
555 Lavigne, Serge Jennes, Martin Zizi, and Jean-Paul Pirnay. 2014. Experimental phage
556 therapy of burn wound infection: difficult first steps. *International journal of burns and*
557 *trauma* 4 (2):66.
- 558 Rossolini, G. M., F. Arena, P. Pecile, and S. Pollini. 2014. Update on the antibiotic resistance crisis.
559 *Curr Opin Pharmacol* 18:56-60.
- 560 Seed, K. D. 2015. Battling Phages: How Bacteria Defend against Viral Attack. *Plos Pathogens* 11
561 (6).
- 562 Smith, E. E., D. G. Buckley, Z. Wu, C. Saenphimmachak, L. R. Hoffman, D. A. D'Argenio, S. I.
563 Miller, B. W. Ramsey, D. P. Speert, S. M. Moskowitz, J. L. Burns, R. Kaul, and M. V. Olson.
564 2006. Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis

- 565 patients. *Proceedings of the National Academy of Sciences of the United States of America*
566 103 (22):8487-92.
- 567 Strateva, T. and D. Yordanov. 2009. *Pseudomonas aeruginosa* - a phenomenon of bacterial
568 resistance. *Journal of medical microbiology* 58 (Pt 9):1133-48.
- 569 Taj, Muhammad Kamran, Zohra Samreen, Taj Muhammad Hassani, Imran Taj, and Wei Yunlin.
570 2014. QUORUM SENSING EFFECT THE LYSIS MECHANISM OF T4
571 BACTERIOPHAGE. *International Journal of Innovation and Scientific Research* 10
572 (2):421-424.
- 573 Tan, D., S. L. Svenningsen, and M. Middelboe. 2015. Quorum Sensing Determines the Choice of
574 Antiphage Defense Strategy in *Vibrio anguillarum*. *MBio* 6 (3):e00627.
- 575 R: A language and environment for statistical computing. R Foundation for Statistical Computing,
576 Vienna, Austria.
- 577 Turner, K. H., J. Everett, U. Trivedi, K. P. Rumbaugh, and M. Whiteley. 2014. Requirements for
578 *Pseudomonas aeruginosa* acute burn and chronic surgical wound infection. *PLoS Genet* 10
579 (7):e1004518.
- 580 Vasse, M., C. Torres-Barcelo, and M. E. Hochberg. 2015. Phage selection for bacterial cheats leads
581 to population decline. *Proceedings of the Royal Society B-Biological Sciences* 282 (1818).
- 582 Yoshida, T., N. G. Hairston, and S. P. Ellner. 2004. Evolutionary trade-off between defence against
583 grazing and competitive ability in a simple unicellular alga, *Chlorella vulgaris*. *Proceedings*
584 *of the Royal Society B-Biological Sciences* 271 (1551):1947-1953.

585

586 **FIGURE LEGENDS**

587

588 **Figure 1.** The comparison of *P. aeruginosa* (panels a and b) and total bacterial population densities
589 (panel c) in the end of the selection experiment between different treatments (CFU denotes for

590 colony forming units per mL). Panel c shows the mean over all competition treatments for PAO1
591 and *lasR* strains, respectively. All bars show ± 1 s.e.m.

592



593 **Figure 2.** Phage population densities in PAO1 (panel a) and *lasR* (panel b) focal pathogen
594 communities in the absence and presence of competitors (PFU denotes for plaque forming units,
595 i.e., phage particles per mL). All bars show ± 1 s.e.m.


596


597 **Figure 3.** The resistance of evolved PAO1 (light grey) and *lasR* (dark grey) strains to ancestral and
598 coevolved phages measured at the end of the experiment. Competition treatment shows the absence
599 and presence of competitors during the selection experiment. Only populations that had evolved in
600 the presence of phage were used for the analysis; all *P. aeruginosa* populations that had evolved in
601 the absence of phage were susceptible to phages. All bars show ± 1 s.e.m.

602

603 **Figure 4.** The cost of adaptation measured in terms of maximum population density after 48h of
604 growth. Panel (a) shows the growth of evolved PAO1 and panel (b) the growth of evolved *lasR*
605 strain in the absence of phage or competitors at the end of the selection experiment. Phage and
606 competition treatments denote the absence and presence of a phage and competitors during the
607 selection experiment. All bars show ± 1 s.e.m.








P. aeruginosa growth in the absence of phage or competitors (OD 600nm)

a) PAO1 strain

Evolutionary Applications

b) *lasR* strain

Page 28 of 29



ID: EVA-2016-106-OA.R1

Title: Bacterial competition and quorum-sensing signalling shapes the eco-evolutionary outcomes of model in vitro phage therapy

Dear Dr. Friman:

It is my pleasure to accept your manuscript for publication in Evolutionary Applications. Your paper will now move to the next stage in the production process. Your manuscript files will be checked to ensure that they are ready for publication. We may contact you if updated versions of files are required. Please contact the journal office (evolappl@wiley.com) if you have any questions.

Your article cannot be published until the publisher has received the appropriate signed license agreement. Once your article has been received by Wiley for production the corresponding author will receive an email from Wiley's Author Services system which will ask them to log in and will present them with the appropriate license for completion.

We would be interesting in receiving your photo contribution(s) for use on an Evolutionary Applications issue eCover, related journal promotional materials and the website. Please send your photo contribution (along with a photo caption and photo credit) to evolappl@wiley.com, and in your email please indicate that you permit us to use your contribution for the uses specified above.

Thank you for choosing Evolutionary Applications for publishing your best work, and we look forward to your continued contributions to the journal.

Sincerely,
Dr. Louis Bernatchez
Editor in Chief, Evolutionary Applications
Louis.Bernatchez@bio.ulaval.ca

ASSOCIATE EDITOR COMMENTS

Associate Editor

Comments to the Author:

Thank you for your thoughtful and thorough revision. I think you've done an excellent job of incorporating the suggestions, and that the manuscript is greatly improved. I am confident that this work will make a nice contribution to the literature, and thank you for submitting your work to Evolutionary Applications.

Response: We thank both Editor and Associate Editor for the acceptance of the manuscript

***Best,
Ville Friman and Rachel Mumford***